



RECEIVED

MAY 08 2003

OCKET NO.: PRD-0003/ORT-1060

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Alain T. Luxembourg, et al.

Application No.: 09/434,965

Filing Date: November 5, 1999

For: PURIFICATION OF ANTIGEN-SPECIFIC T CELLS

Confirmation No.: 4589

Group Art Unit: 4589

Examiner: DeCloux, Amy M.

DATE OF DEPOSIT: May 2, 2003

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,  
ON THE DATE INDICATED ABOVE AND IS  
ADDRESSED TO THE COMMISSIONER OF PATENTS  
AND TRADEMARKS, WASHINGTON, DC 20231.

Felicity E. Groth  
TYPED NAME: Felicity E. Groth  
REGISTRATION NO.: 47,042

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with  the first or  second After Final Submission, therefore:
  - Certification in Accordance with § 1.97(e) is attached; or
  - The fee of \$180.00 as set forth in § 1.17(p) is attached.
- In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:
  - Certification in Accordance with § 1.97(e) is attached;
  - or
  - The fee of \$180.00 as set forth in § 1.17(p) is attached.
- In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- Copies of references listed on the attached Form PTO-1449 are enclosed herewith

EXCEPT THAT:


- In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. , filed .
- If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Enclosed is a copy of the PCT International Search Report dated **October 29, 1997** and a copy of the EPO European Search Report dated **May 21, 2002**, which indicates the references to be relevant.

There are no listed references which are not in the English language.

Date: May 2, 2003

  
Felicity E. Groth  
Felicity E. Groth  
Registration No. 47,042

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

© 2003 WW



RECEIVED

MAY 08 2003

**TECH CENTER 1600/2900**

Sheet 2 of 2

<b>Form PTO-1449 Modified</b>	Docket No. <b>PRD-0003/ORT-1060</b>	Application No. <b>09/434,965</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	Applicant <b>Alain T. Luxembourg, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office	Filing Date <b>November 5, 1999</b>	Group <b>4589</b>

## **U. S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document No.	Date	Country	Translation	
				YES	NO
61	CA 2 069 541	11/27/93	Canada		
62	EP 0 814 838	01/07/98	EPO		
63	WO 96/05287	02/22/96	PCT		
64	WO 96/27392	09/12/96	PCT		

**EXAMINER**

**DATE CONSIDERED**



**RECEIVED**

MAY 08 2003

**TECH CENTER 1600/2900**

Sheet 1 of 2

<b>Form PTO-1449 Modified</b>		Docket No. <b>PRD-0003/ORT-1060</b>	Application No. <b>09/434,965</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Alain T. Luxembourg, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>November 5, 1999</b>	Group <b>4589</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>56</b>	Luxembourg, A.T. et al., "Biomagnetic Isolation of Antigen-Specific CD8 + T Cells Usable in Immunotherapy", <i>Nature Biotechnology</i> , 1998, 16(3), 281-285, XP-002198433	
	<b>57</b>	Nag, B. et al., "Stimulation of T Cells by Antigenic Peptide Complexed with Isolated Chains of Major Histocompatibility Complex Class II Molecules", <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90(4), 1604-1608	
	<b>58</b>	Stryhn, A. et al., "Preformed Purified Peptide/Major Histocompatibility Class I Complexes are Potent Stimulators of Class I-Restricted T Cell Hybridomas", <i>Eur. J. Immunol.</i> , 1994, 24(6), 1404-1409, XP-008003084	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	